Ingredion Beats Q2 Sales Estimates, Reaffirms 2026 Outlook
INGR is trading near its 52-week low of $94.44 (6.2% above the low).
Summary
Ingredion posted Q2 sales of $1.85 billion, edging past the $1.83 billion consensus, while adjusted EPS slipped to $2.82 from $2.87 a year ago. The company reaffirmed its full-year 2026 guidance, calling for reported EPS of $9.15 to $9.75 and adjusted EPS of $10.30 to $10.90, with net sales flat to up low single digits. This follows a transformative quarter that included the $3.6 billion Tate & Lyle acquisition and the sale of a majority stake in its Pakistan business. The sales beat and steady outlook suggest the core business is holding up despite production challenges at the Argo facility and currency headwinds in Latin America. With the stock trading at 9 times forward earnings, the reaffirmed guidance provides a floor for estimates as the Tate & Lyle integration begins.
At the time of this announcement, INGR was trading at $100.34 on NYSE in the Manufacturing sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $94.44 to $130.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.